Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Preorchiectomy Leydig Cell Dysfunction in Patients With Testicular Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Long-term neurotoxicity and quality of life in testicular cancer survivors-a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Small RNAs in Seminal Plasma as Novel Biomarkers for Germ Cell Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Late adverse effects and quality of life in survivors of testicular germ cell tumour

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Adverse health behaviours in long-term testicular cancer survivors: a Danish nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Compensated Leydig cell (LC) dysfunction, defined by elevated serum levels of luteinizing hormone (LH) in combination with normal total testosterone levels, is common in testicular cancer (TC) survivors. The association between this condition and quality of life is unknown. We aimed to clarify if TC survivors with compensated LC dysfunction have impaired quality of life.

PATIENTS AND METHODS: In total, 147 long-term TC survivors were included. On the basis of a single measurement of testosterone and LH, compensated LC dysfunction was defined by age-adjusted levels of LH above normal range combined with testosterone levels within the normal range. Quality-of-life outcomes including sexual function, anxiety and depression, fatigue, and overall self-evaluated quality of life were compared between patients with and without compensated LC dysfunction with adjustment for age.

RESULTS: In total, 60 TC survivors had compensated LC dysfunction and 87 TC survivors had normal LC function. TC survivors with compensated LC dysfunction had lower serum levels of total testosterone (11 vs. 13 nmol/L, P = .016). There were no significant differences in the investigated quality-of-life outcomes (anxiety, depression, sexual function, fatigue) between the 2 groups.

CONCLUSION: Compensated LC dysfunction in TC survivors was not associated with symptoms of depression, anxiety, sexual dysfunction, fatigue, or impaired overall self-evaluated quality of life. Limitations include the few cases of symptoms of depression (n = 7). Our findings do not suggest that testosterone substitution is indicated in TC survivors with compensated LC dysfunction.

OriginalsprogEngelsk
TidsskriftClinical Genitourinary Cancer
Vol/bind17
Udgave nummer1
Sider (fra-til)e65-e71
ISSN1938-0682
DOI
StatusUdgivet - feb. 2019

ID: 55865062